Research programme: immunotherapeutic vaccines - UbiVac

Drug Profile

Research programme: immunotherapeutic vaccines - UbiVac

Alternative Names: DPV 002; DPV 003; DPV-003HPV; DPV-004

Latest Information Update: 12 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UbiVac
  • Class Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Human papillomavirus infections

Most Recent Events

  • 12 Sep 2016 Preclinical trials in Human papillomavirus infections in USA (Parenteral) (UbiVac pipeline, September 2016)
  • 12 Sep 2016 UbiVac plans a phase II trial for DPV 002 in Breast cancer (Combination therapy) in USA (UbiVac pipeline, September 2016)
  • 28 Oct 2015 Preclinical trials in Cancer in USA (Parenteral) before October 2015 (UbiVac pipeline, october 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top